Assembly climbs on quarterly revenue beat - ASMB News | RalliesAssembly climbs on quarterly revenue beat
A
ASMB• Quarterly revenue beats estimates
- Shares of drug developer Assembly Biosciences ASMB.O advance 4.6% to $31.32
- ASMB's Q2 revenue from collaborative research with Gilead GILD.O rose to $13.4 million from year-ago $9.6 million
- Analysts on average expected $8.6 million in revenue, according to LSEG data
- Co says revenue increase includes a $5.1 million catch-up adjustment for updated estimate of future activities under the Gilead partnership
- Reports Q2 loss of 20 cents/shr vs est. 65 cents/shr
- Including session's move, stock up 11.8% YTD
DVLT
•
